Correction to: Atopic dermatitis and autoimmunity: the occurrence of autoantibodies and their association with disease severity [PDF]
James Holmes +2 more
openalex +1 more source
Calhm6 drives M2 macrophage polarization via the Chp1‐Camk4‐Creb1 axis, suppressing inflammation through calcium‐dependent ectosomal delivery. Calhm6 deficiency enhances M1 responses, boosting bactericidal activity but exacerbating tissue damage. LPS/IFNγ upregulate Calhm6 via Irf1, while IL‐4/Stat6 inhibits it, balancing immune outcomes.
Yanlong Xin +14 more
wiley +1 more source
From chaos to control: Nobel insights in regulatory T cells and immune tolerance. [PDF]
Estrada Brull A, Joller N.
europepmc +1 more source
Dysregulated Tissue resident macrophage (TRMs) link to autoimmune inflammation. SMURF2 mediates Lys‐27 (K27)‐linked ubiquitination of p‐TBK1 and its degradation, which inhibits CSF1R signaling‐triggered TRM proliferation, thereby restraining the autoimmune inflammation.
Xiang An +8 more
wiley +1 more source
Anti-cytolethal distending toxin antibodies in systemic sclerosis: associations with gastrointestinal disease and immune dysregulation. [PDF]
Di Ciommo FR +9 more
europepmc +1 more source
Heterogeneity of aquaporin-4 autoimmunity and spinal cord lesions in multiple sclerosis in Japanese [PDF]
Tatsuomi Matsuoka +10 more
openalex +1 more source
CircSMEK1 Suppresses HCC via the hnRNPK‐IGF2‐AKT Axis: A Diagnostic Biomarker and Therapeutic Target
CircSMEK1 is downregulated in MASH/HCC and predicts poor prognosis. It suppresses tumor progression by promoting hnRNPK ubiquitination and inhibiting the IGF2/PI3K/AKT axis, while its loss activates immunosuppressive cancer‐associated fibroblasts. Serum circSMEK1 serves as a non‐invasive diagnostic biomarker, and its restoration potently inhibits HCC ...
Peilan Guo +15 more
wiley +1 more source
Autoimmunity and Autoimmune Disease [PDF]
openaire +3 more sources
Disruption of the mRNA m6A writer complex triggers autoimmunity in Arabidopsis. [PDF]
Metheringham CL +6 more
europepmc +1 more source
TSHR‐Targeting Nucleic Acid Aptamer Treats Graves' Ophthalmopathy via Novel Allosteric Inhibition
This study presents YC3, a novel inhibitory TSHR‐targeting aptamer, as a promising therapeutic for Graves' ophthalmopathy (GO). YC3 suppresses pathological phenotypes in human orbital fibroblasts and improves outcomes in GO mice by binding to a previously unidentified allosteric site on TSHR, demonstrating the potential of aptamers in advancing ...
Yanchen Zhang +16 more
wiley +1 more source

